The reference to out-sourcing of contracts probably refers to something else. As far as genotyping is concerned, from the 10K:
"We will accomplish our analysis of individual SNPS, as previously defined under "Our Research and Development Approach", through ultra-high throughput (UHT) machines. Genotyping consists of two phases: screening, wherein a relatively small number of cases and controls are genotyped at a large number of SNPs, and validation, wherein a considerably larger number of cases and controls are genotyped at a small number of SNPs. The Orchid UHT machine we purchased and installed at DNAprint Genomics, for example, will accomplish validation genotyping."
"Our Plan of Operations over the next twelve months will focus on common cancers such as lung, prostate, colon, breast and pancreas. We will conduct screening genotyping, followed by validation genotyping."
In the plan of operations section they also provide a breakdown of estimated expenses of $1,403,907 over the
next year (to be met from the ADOT and Pierpoint funding and from any revenues). This includes the amount of $800,000 for genotyping. Note that the corresponding estimate for genotyping in the last 10Q was $2,000,000.
So, we know that genotyping will take place this year. We do not know what the percentage split is between "screening" and "validation genotyping" so therefore cannot estimate what percentage of the total genotyping might be contracted to DNAP. We also do not know for certain that DNAP will be the party selected for this work, or if the work might be shared between multiple people. We can reasonably suspect though that DNAP will get at least some of this work. Thus all that we can say is that DNAP will possibly get an unknown share of $800,000 worth of genotyping work this year.
